期刊
MEDICAL ONCOLOGY
卷 39, 期 5, 页码 -出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-022-01652-9
关键词
Polyploid giant cells; Leukemia; Cancer
类别
资金
- Office of the Director, National Institutes of Health (NIH) [S10RR027050]
- NIH of Columbia University Irving Medical Center, New York [P30 CA013696]
Polyploid giant cancer cells (PGCC) are a unique type of cells observed in cancer, arising when cells are stressed and playing a key role in tumor progression.
Giant cells with polyploidy, termed polyploid giant cells, have been observed during normal growth, development, and pathologic states, such as solid cancer progression and resistance to therapy. Functional studies of polyploidal giant cancer cells (PGCC) provided evidence that they arise when normal diploid cells are stressed, show stem cell-like properties, and give rise to tumors. In the present study, we report in K562 leukemia cell line that introduction of the hotspot K700E mutation in the gene SF3B1 using CRISPR/Cas9 method results in an increased frequency of multinucleated polyploid giant cells resistant to chemotherapeutic agent and serum starvation stress. These giant cells with higher ploidy are distinct from multinucleated megakaryocytes, are proliferative, and are characterized by increased accumulation of mitochondria. PGCC have been previously documented in solid tumors. This is the first report describing PGCCs in a cell line derived from a liquid cancer where increased frequency of PGCCs is linked to a specific genetic event. Since SF3B1 mutations are predominantly seen in MDS and other hematologic malignancies, our current findings will have significant clinical implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据